Tuesday, November 2, 2021

Sanofi, GSK face COVID-19 vaccine trial delay

Sanofi and GlaxoSmithKline (GSK) have delayed their COVID-19 vaccine programme after phase I/II results found a low immune response in older adults who received their investigational vaccine.

In a phase I/II study of Sanofi/GSK’s adjuvanted recombinant protein-based vaccine, interim results found the jab induced an immune response comparable to recovered COVID-19 patients in adults aged 18 to 49 years.

However, the results also found that the vaccine did not have the same effect in older adults, who demonstrated low immune responses – likely due to an ‘insufficient concentration of antigen’, according to the Sanofi/GSK.

The companies have now decided to plan a phase IIb study, expected to begin in February 2021, to test an improved antigen formulation which recently showed promise in a recent challenge study in non-human primates.

In this challenge study, the improved antigen formulation demonstrated protection against lung pathology and lead to rapid viral clearance from the nasal passages and lungs within two to four days.

‘These results increase the Companies confidence in the capacity of the adjuvanted recombinant platform to deliver a highly efficient vaccine for all adults,’ the companies commented in a statement issued today.

The phase IIb study, in addition to testing the improved antigen formulation, will include a proposed comparison with an authorised COVID-19 vaccine.

If the data in this mid-stage study is positive, Sanofi/GSK expect a that a phase III study could start in the second quarter of 2021.

Depending on the results in phase III, regulatory submissions could be expected in the second half of 2021, which will delay the vaccine’s potential availability from the previously anticipated mid-2021 to the end of 2021.

“The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile,” said Roger Connor, president of GSK Vaccines.

“It is also clear that multiple vaccines will be needed to contain the pandemic. Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19,” he added.

Source link

Latest Articles

Widely used chemical linked to 1,00,000 US deaths per year: Study

NEW YORK: Daily exposure to phthalates, a group of chemicals used in everything from plastic containers to makeup, may lead to approximately 100,000 deaths...

Foods to Reduce Inflammation and Strengthen the Immune System

Did you know that you can greatly reduce inflammation and boost your immune system by simply incorporating more anti-inflammatory foods and beverages into your...

Personal Selling

INTRODUCTION Early sellers and traders were not held in high esteem. The Roman word for salesman meant ‘Cheater’ and...

Building Muscle on a Vegan Diet

There are a lot of  misconceptions surrounding veganism. The notion that those who practice it are lacking in protein and therefore muscles is the...

Electrodes in brain new hope for severe cases of epilepsy

Neurosurgeons at All India Institute of Medical Sciences have devised a new technique for operating on children suffering from a severe form of epilepsy...